The clinical efficacy of tolterodine extended-release is maintained for 24 h in patients with overactive bladder
Article first published online: 5 JUN 2007
Volume 100, Issue 1, pages 107–110, July 2007
How to Cite
Dmochowski, R., Kreder, K., MacDiarmid, S., Carlsson, M. and Guan, Z. (2007), The clinical efficacy of tolterodine extended-release is maintained for 24 h in patients with overactive bladder. BJU International, 100: 107–110. doi: 10.1111/j.1464-410X.2007.06926.x
- Issue published online: 5 JUN 2007
- Article first published online: 5 JUN 2007
- Accepted for publication 25 January 2007
- bladder diaries;
- overactive bladder;
- tolterodine extended-release
To assess the 24-h efficacy of tolterodine extended-release (ER) in patients with overactive bladder (OAB) and urgency urinary incontinence (UUI).
PATIENTS AND METHODS
We conducted a post hoc analysis of a 12-week, placebo-controlled trial of tolterodine-ER in patients with frequency (≥8 voids/24 h) and UUI (≥5 episodes/week) for ≥ 6 months. Seven-day bladder diaries were used to record diary endpoints; 24-h diary data were stratified by 6-h periods beginning at midnight.
Compared with placebo (508 patients), tolterodine-ER (507 patients) significantly and consistently increased volume voided per void and reduced UUI episodes and micturition frequency during each interval.
These results indicate that tolterodine-ER maintained clinical efficacy over 24 h and should be effective for OAB symptoms without regard to whether symptoms occur during the day or at night.